Donepezil Hydrochloride Tablet
Product Images NDC 71093-128

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 71093-128). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aci Healthcare Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container Label-10mg1000s (10mg 1000s)

This is a label for Donepezil Hydrochloride tablets, a medication that comes in 2mg and 5mg doses, made by ACH Healthcare USA. The label includes a caution to keep the medication out of reach of children.*

FDA Label Image

Container Label-10mg30s (10mg 30s)

FDA Label Image

Container Label-10mg500s (10mg 500s)

FDA Label Image

Container Label-10mg90s (10mg 90s)

This is a medicine information of Donepezil Hydrochloride Tablets, USP with a total of 90 tablets. The label includes the product code NC710531288 and the manufacturer name "Bonly". There is also a reference to the "NO VARNISH ZONE" and a space to input batch details. The text appears to have been scanned, resulting in some non-readable characters.*

FDA Label Image

Container Label-5mg1000s (5mg 1000s)

FDA Label Image

Container Label-5mg30s (5mg 30s)

FDA Label Image

Container Label-5mg500s (5mg 500s)

This is a pharmaceutical label for Donepezil Hydrochloride Tablets, USP produced by the fictitious company, NOCTI0S42745 Ronly. The medication contains 500 tablets and is intended for adults. The label includes the caution to keep the medication out of reach of children.*

FDA Label Image

Container Label-5mg90s (5mg 90s)

This is a medication label for Donepezil Hydrochloride Tablets, which are used for treating dementia in individuals with Alzheimer's disease. The label includes information for proper usage and storage of the medication.*

FDA Label Image

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)

FDA Label Image

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)

The text is describing a graph showing the cumulative percentage of patients taking a medication called Donepezil Hydrochloride 10 mg/day compared to a placebo. The graph also shows the change in ADCS-ADL from baseline, with a range from -10 to +5.*

FDA Label Image

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)

FDA Label Image

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)

The text provides a graph showing the Cumulative Percentage of Patients on the Y-axis and SIB Change from Baseline on the X-axis. The graph has a range of 0-100 on the Y-axis and 0-60 on the X-axis. It appears to be a representation of the distribution of the response to treatment of a particular condition.*

FDA Label Image

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)

FDA Label Image

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)

FDA Label Image

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)

This is a record of a medical evaluation for patients, indicating a percentage of improvement, and a rating called "CIBIC-plus". However, due to the presence of multiple errors and scattered text fragments, the information is not clear or complete.*

FDA Label Image

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)

FDA Label Image

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)

FDA Label Image

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)

This appears to be a table displaying the percentage of patients taking different medications and their level of improvement according to the CIBIC-plus rating. The medications listed are Donepezil Hydrochloride at 10mg/day and 5mg/day, as well as a placebo. The table indicates the percentage of patients with varying levels of improvement, ranging from "markedly improved" to "markedly worse."*

FDA Label Image

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)

The text appears to be a table showing the mean change from baseline for clinical improvement after 3 months of drug treatment with either donepezil hydrochloride (10mg/day) or placebo, indicated by symbols (-e- for donepezil and -o- for placebo). However, as there are no corresponding numerical values provided, the information is not complete and cannot be fully interpreted.*

FDA Label Image

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)

The text represents a chart showing the Cumulative Percentage of Patients treated with Donepezil Hydrochloride 10 mg/day and Placebo, and the SIB (Severe Impairment Battery) Change from Baseline. The chart displays the percentage of patients on the Y-axis, ranging from 0% to 100%, and the SIB Change from Baseline on the X-axis, ranging from 5 to 75. However, there is not enough information to interpret the chart accurately, and no additional context is available.*

FDA Label Image

Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)

FDA Label Image

Chemical Structure (Donepezil Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.